“When breast cancer is diagnosed early, survival after treatment is excellent, over 90% in some countries, 2” according to Patrick Toubiana, MD, Radiologist, President and Co-Founder at the C.S.E.

Designed for seamless integration in clinical workflow, ProFound AI results can be flexibly integrated into leading MIS/RIS, and PACS software products. Both scores are designed to assist with clinical decision making Case Scores may also be used to prioritize the reading worklist. Each case also includes a Case Score, which indicates the algorithm’s confidence level for the case matching malignant cases within the ProFound AI database. Each identified region includes a Certainty of Finding score, which indicates its match to lesions within the growing ProFound AI enriched database. Suspicious appearing structures such as densities (masses, architectural distortions, and asymmetries) and calcification clusters are identified via a contoured line. 1 The advanced deep-learning software uses advanced neural network image processing and pattern recognition to analyze mammography images for potential cancers. The latest generation of ProFound AI for 2D Mammography outperforms the previous product version, offering standalone performance improvements of up to 4% increased sensitivity, up to 10% improved specificity and up to 40% faster processing. “By using this leading-edge technology, both general and breast radiologists can potentially improve their accuracy and performance, which may in turn have a positive impact on women and the healthcare system overall.” “The European launch of our third generation of ProFound AI for 2D Mammography demonstrates iCAD’s steadfast commitment to improving breast cancer detection for all women worldwide,” said Stacey Stevens, President of iCAD, Inc. In addition, the Company will showcase its most recent technological advancements, including the latest generations of ProFound AI® for Digital Breast Tomosynthesis (DBT) and ProFound AI® Risk, in its booth (#226A). (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will unveil the latest generation of ProFound AI® for 2D Mammography at the Journées Francophones de Radiologie (JFR) meeting in Paris, Oct. Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

Icad mammography